NAFLD / MASLD and Mental Health: The Overlap Between Liver Disease and Depression, Anxiety, and Cognitive Decline

Why MASLD and Mental Health Are Connected

Depression, anxiety, and cognitive complaints appear far more often in people with metabolic liver disease than in the general population. This is not coincidental. A 2022 meta-analysis published in the Journal of Affective Disorders (N=2,041,752) found that NAFLD was associated with a 1.13-fold increased risk of depression after adjusting for metabolic confounders [1]. Smaller cohort studies report odds ratios as high as 2.83 for major depressive disorder in biopsy-confirmed NASH patients versus steatosis-free controls [2].

The connection runs in both directions. Depression and anxiety accelerate weight gain, reduce treatment adherence, and worsen glycemic control, all of which promote hepatic fat accumulation. Meanwhile, the liver itself generates inflammatory signals that reach the central nervous system. This bidirectional relationship means that addressing only the liver or only the mood disorder leaves the other condition poorly controlled.

The 2023 nomenclature shift from NAFLD to MASLD, endorsed by a multi-society Delphi consensus, explicitly tied the diagnosis to cardiometabolic risk factors (BMI ≥25, type 2 diabetes, hypertension, dyslipidemia) [3]. Every one of those risk factors independently predicts worse psychiatric outcomes. The renamed condition makes the metabolic-psychiatric overlap harder to ignore.

The Inflammatory Bridge: How Liver Fat Alters Brain Chemistry

Hepatic steatosis triggers a cascade of systemic inflammation that does not stop at the liver capsule. Kupffer cells and hepatic stellate cells release tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and C-reactive protein (CRP) into the circulation. A cross-sectional analysis from the NHANES III cohort showed that participants with ultrasound-defined NAFLD had significantly higher serum CRP and IL-6 levels, both of which correlated with Patient Health Questionnaire-9 (PHQ-9) depression scores [4].

These cytokines cross the blood-brain barrier. Once in the central nervous system, TNF-alpha and IL-6 activate microglia, reduce serotonin synthesis by shunting tryptophan toward the kynurenine pathway, and impair hippocampal neurogenesis. The result is a neuroinflammatory state that clinically presents as depressed mood, anhedonia, fatigue, and slowed cognition.

Insulin resistance amplifies the problem. The brain depends on intact insulin signaling for synaptic plasticity and glucose uptake. In MASLD, peripheral hyperinsulinemia downregulates cerebral insulin receptors, a mechanism also implicated in Alzheimer's disease. A 2021 study in Metabolism (N=454) demonstrated that HOMA-IR scores above 2.5 predicted both hepatic steatosis on MRI-PDFF and lower Montreal Cognitive Assessment (MoCA) scores in the same patients [5].

The gut-brain-liver axis provides a third pathway. Intestinal dysbiosis, common in MASLD, increases gut permeability and allows bacterial endotoxins (lipopolysaccharide) to enter the portal circulation. This endotoxemia drives hepatic inflammation and, through vagal afferents and systemic cytokine signaling, alters central neurotransmission. Probiotic interventions that reduce endotoxemia have shown modest improvements in both liver enzymes and anxiety scores in pilot trials, though large RCTs are still needed [6].

Depression in MASLD: Prevalence, Screening, and Clinical Impact

Depression is the best-studied psychiatric comorbidity in metabolic liver disease. The prevalence of clinically significant depressive symptoms (PHQ-9 ≥10) in NAFLD cohorts ranges from 17% to 27%, compared with roughly 8% in the age-matched general population [7]. In patients with biopsy-confirmed NASH, the rate climbs higher.

Dr. Zobair Younossi, a hepatologist at Inova Health System and lead author of multiple NAFLD burden-of-disease analyses, has stated: "Depression and fatigue are the two patient-reported outcomes that most consistently impair quality of life in NAFLD, yet they are rarely addressed in hepatology practice" [8].

Depression also predicts disease progression. A prospective Korean cohort study (N=142,957) published in the Journal of Hepatology found that participants with baseline depressive symptoms had a 1.38-fold higher risk of incident fatty liver disease over 8.7 years of follow-up, suggesting that mood disorders may accelerate hepatic fat deposition through behavioral and neuroendocrine pathways [9].

Screening remains inadequate. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on NAFLD acknowledges the impact of depression on treatment adherence but stops short of mandating routine psychiatric screening [10]. The American Diabetes Association (ADA) Standards of Care 2024 recommends annual depression screening for all patients with diabetes, a population that substantially overlaps with MASLD [11]. Clinicians treating MASLD should adopt this same standard.

A validated two-question screen (PHQ-2) takes under 60 seconds. Patients who score 3 or above proceed to the full PHQ-9. This simple step identifies a modifiable driver of non-adherence to diet, exercise, and medication regimens that directly influence liver outcomes.

Anxiety, Stress, and the MASLD Patient Experience

Anxiety receives less research attention than depression in hepatology, but the data that exist are striking. A 2020 systematic review in Clinics and Research in Hepatology and Gastroenterology found that 37.2% of NAFLD patients met criteria for generalized anxiety disorder (GAD) by structured interview, roughly triple the population rate [12].

The diagnosis itself generates distress. Patients told they have "fatty liver" often catastrophize about cirrhosis and liver cancer. The word "disease" in NAFLD/MASLD compounds this fear. Health anxiety is particularly pronounced in patients who undergo liver biopsy, a procedure that carries its own anticipatory stress.

Cortisol dysregulation compounds the metabolic picture. Chronic anxiety activates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol output. Cortisol promotes visceral adiposity, hepatic de novo lipogenesis, and insulin resistance. This creates a feed-forward loop: liver fat triggers anxiety, anxiety raises cortisol, and cortisol drives more liver fat.

Cognitive behavioral therapy (CBT) adapted for chronic medical illness can break this loop. A small Italian RCT (N=39) randomized NAFLD patients to structured CBT plus lifestyle counseling versus lifestyle counseling alone. The CBT group showed significantly greater reductions in both GAD-7 scores and ALT levels at 24 weeks [13]. The trial was underpowered for histological endpoints, but the biochemical signal supports integration of psychological interventions into MASLD care.

Cognitive Impairment: Beyond "Brain Fog"

Patients with MASLD frequently report difficulty concentrating, word-finding problems, and mental sluggishness. These subjective complaints have objective correlates. A 2019 cross-sectional study in Liver International (N=217) found that NAFLD patients without cirrhosis scored significantly lower on psychometric tests of attention, processing speed, and working memory compared with metabolically matched controls without steatosis [14].

This is distinct from hepatic encephalopathy. Patients with compensated MASLD and normal ammonia levels still demonstrate measurable cognitive deficits. The proposed mechanism involves neuroinflammation and cerebral insulin resistance rather than hyperammonemia.

Fibrosis stage matters. Data from the CARDIA study (Coronary Artery Risk Development in Young Adults, N=877) showed that participants with higher FIB-4 scores at midlife had steeper cognitive decline over the next decade, independent of cardiovascular risk factors [15]. This suggests that hepatic fibrosis, even subclinical, may be an underrecognized contributor to age-related cognitive decline.

The clinical implication is straightforward: cognitive complaints in a MASLD patient deserve formal evaluation rather than dismissal. The MoCA is a 10-minute bedside screen that can identify deficits warranting neuropsychological referral.

Fatigue: The Most Common and Least Treated Symptom

Over 50% of patients with NAFLD report clinically significant fatigue, making it the single most prevalent symptom. Yet hepatology guidelines devote minimal space to it. Fatigue in MASLD correlates poorly with ALT levels, fibrosis stage, or steatosis grade, which means standard liver tests do not predict who suffers most [16].

The fatigue appears to be central rather than peripheral. A UK study using transcranial magnetic stimulation (TMS) in 30 NAFLD patients demonstrated reduced corticomotor excitability compared with healthy volunteers, suggesting that central neural pathways are directly affected [17]. Patients describe the experience as distinct from simple sleepiness: it is an inability to initiate and sustain effort, even after adequate sleep.

Obstructive sleep apnea (OSA) contributes in a subset. The prevalence of OSA in MASLD exceeds 50% and correlates with both daytime somnolence and more severe hepatic steatosis. All MASLD patients reporting fatigue should be screened with the STOP-Bang questionnaire. Treatment with continuous positive airway pressure (CPAP) improves not only sleepiness but also aminotransferase levels in compliant patients [18].

Exercise is the single most evidence-supported intervention for NAFLD-related fatigue. A meta-analysis of 20 RCTs found that structured aerobic exercise (150 minutes per week at moderate intensity) reduced intrahepatic triglyceride content by a mean of 3.31 percentage points and significantly improved fatigue and quality-of-life scores [19]. The challenge is that fatigue itself is a barrier to exercise, making motivational support and graded activity programs essential.

Treatment Approaches That Address Both Liver and Brain

GLP-1 receptor agonists occupy a unique position in MASLD care because they improve hepatic, metabolic, and psychiatric parameters simultaneously. Semaglutide 0.4 mg daily (subcutaneous) resolved NASH without worsening fibrosis in 59% of patients versus 17% on placebo in a phase 2 trial (N=320) published in the New England Journal of Medicine [20]. Separately, a Danish nationwide cohort study (N=35,252) found that GLP-1 RA users had a 22% lower incidence of new depression diagnoses compared with matched non-users, after adjusting for BMI and diabetes status [21].

The mechanism may involve direct central GLP-1 receptor activation. GLP-1 receptors are expressed in the hippocampus, amygdala, and nucleus tractus solitarius. Preclinical models show that GLP-1 RA administration reduces neuroinflammation and increases BDNF expression, offering a plausible route for mood improvement independent of weight loss [22].

Pioglitazone, a PPAR-gamma agonist recommended by the AASLD for non-cirrhotic NASH, also carries neuropsychiatric data. A 2023 meta-analysis in Diabetes Care reported that pioglitazone use was associated with a 25% reduction in incident dementia risk in patients with type 2 diabetes [23]. Its effects on cerebral insulin sensitization parallel its hepatic benefits.

Resmetirom (Rezdiffra), the first FDA-approved therapy specifically for MASH with moderate-to-advanced fibrosis (F2-F3), targets thyroid hormone receptor beta in hepatocytes [24]. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily achieved NASH resolution in 29.9% of patients versus 9.7% on placebo at 52 weeks [25]. Mental health outcomes were not primary endpoints, but thyroid hormone signaling influences cerebral metabolism, and post-hoc analyses of patient-reported outcomes are expected.

Vitamin E (800 IU daily), recommended by the AASLD for non-diabetic, non-cirrhotic NASH, has shown modest anxiolytic effects in preclinical models through its antioxidant action on the CNS, though clinical psychiatric data in NAFLD are lacking [10].

For patients whose depression meets criteria for pharmacotherapy, SSRIs remain first-line. Sertraline and escitalopram have minimal hepatotoxicity risk and do not promote weight gain to the degree that mirtazapine or paroxetine do. Avoiding weight-promoting psychotropics is clinically meaningful when hepatic fat reduction is a therapeutic goal.

The AACE 2023 Consensus Statement on the Management of Obesity recommends that clinicians treating obesity-related complications, including MASLD, screen for and co-manage depression, as untreated depression is a leading cause of failed lifestyle intervention [26].

Building a Dual-Track Care Plan

Managing the liver-brain overlap in MASLD requires coordination between hepatology (or primary care) and behavioral health. A practical framework includes four steps:

Step 1: Screen at diagnosis. Administer the PHQ-2 and GAD-2 at the same visit where MASLD is diagnosed. If either score is 3 or above, complete the full PHQ-9 or GAD-7 and refer appropriately.

Step 2: Address sleep. Use STOP-Bang to identify OSA. Treat with CPAP if the apnea-hypopnea index is 15 or above. This single intervention can reduce fatigue, improve insulin sensitivity, and lower ALT.

Step 3: Prioritize metabolic therapies with CNS co-benefits. When pharmacotherapy is indicated for MASLD (FIB-4 ≥1.3, elevated ALT, or imaging-confirmed steatosis with metabolic risk), GLP-1 receptor agonists and pioglitazone offer dual hepatic-psychiatric value. Resmetirom is indicated for biopsy-confirmed MASH with F2-F3 fibrosis.

Step 4: Prescribe structured exercise with behavioral support. A target of 150 minutes per week of moderate-intensity aerobic activity reduces liver fat and improves mood. Graded exercise therapy, starting at tolerable durations and building incrementally, helps patients with disabling fatigue adhere.

Patients with moderate-to-severe depression or GAD should receive concurrent evidence-based psychotherapy (CBT or behavioral activation) and, when indicated, weight-neutral antidepressants. The hepatologist does not need to deliver this care directly but must ensure it happens through warm referral and follow-up.

Routine PHQ-9 reassessment every 6 months, paired with FIB-4 and metabolic labs, provides an integrated dashboard for tracking both disease axes simultaneously.